SecProbe.io

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 12, 2025

Shaun Passley
Chief Executive Officer
ZenaTech, Inc.
777 Hornby Street, Suite 600
Vancouver, A1, V6Z 1S4

 Re: ZenaTech, Inc.
 Schedule 13D filed January 21, 2025 by Shaun Passley
 File No. 005-94804
Dear Shaun Passley:

 We have conducted a limited review of the above-captioned filing and
have the
following comments.

 Please respond to this letter by amending the filing or by providing
the requested
information. If you do not believe our comments apply to your facts and
circumstances or
that an amendment is appropriate, please advise us why in a response letter.

 After reviewing any amendment to the filing and any information provided
in
response to these comments, we may have additional comments.

Schedule 13D filed January 21, 2025
General

1. We note that the event reported as requiring the filing of the Schedule
13D was
 September 30, 2024. Rule 13d-1(a) of Regulation 13D-G requires the
filing of a
 Schedule 13D within five business days after the date beneficial
ownership of more
 than five percent of a class of equity securities specified in Rule
13d-1(i)(1) was
 acquired. Based on the September 30, 2024 event date, the Schedule 13D
submitted
 on January 21, 2025 was not timely filed. Please advise us why the
Schedule 13D was
 not filed within the required five business days after the date of the
acquisition.
2. We noticed the disclosure provided under Item 2 that indicated the
Schedule 13D was
 "filed on behalf of [the Reporting Persons] pursuant to the listing of
the Issuer's
 common shares on the Nasdaq Capital Market." The date of the Issuer's
Form 8-A that
 registered the subject class of equity is September 26, 2024. The date
of event that
 required the filing of the Schedule 13D, as disclosed on the cover page
of the
 Schedule 13D, however, was September 30, 2024. Please advise us how this
date of
 March 12, 2025
Page 2

 event was determined, and separately advise us why it appears to have
been identified
 as the date that necessitated the filing of the above-captioned Schedule
13D.
Item 5, page 1

3. We note your disclosure in Item 5(c) that "[n]one of the Reporting
Persons has
 effected any other transactions in the Issuer's common shares within the
past 60 days,
 except that Dr. Passley sold 45,447 common shares on or about January 3,
2025
 pursuant to Rule 144." Please revise to provide the requisite disclosure
with respect to
 all transactions in the securities between the deadline for timely
filing the Schedule
 13D and the actual filing of the Schedule 13D. In amending the Schedule
13D to
 include the required disclosures, please be advised that the Instruction
to Item 5(c)
 requires the beneficial owner to "describe," at a minimum, the
following: "(1) The
 identity of the person covered by Item 5(c) who effected the
transaction; (2) the date
 of transaction; (3) the amount of securities involved; (4) the price per
share or unit;
 and (5) where and how the transaction was effected."
 We remind you that the filing persons are responsible for the accuracy
and adequacy
of his disclosures, notwithstanding any review, comments, action or absence of
action by the
staff.

 Please direct any questions to Blake Grady at 202-551-8573 or Nicholas
Panos at
202-551-3266.

 Sincerely,

 Division of
Corporation Finance
 Office of Mergers &
Acquisitions
</TEXT>
</DOCUMENT>